Denali Therapeutics Inc.

NASDAQ:DNLI

Biotechnology

Healthcare
$18.40 +0.40%

+$0.09 today

Market cap
$2.95B
Beta
1.01
P/E (TTM)
-8.7
EPS (TTM)
-$2.72
52W Low $12.58High $24.65

Volume 2.37M

Average 1.84M

DNLI Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Denali Therapeutics Inc.NASDAQ: DNLI

Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q2 FY2026 selling, general & admin of $36.28M rose 12.4% year over year, behind the +19.2% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 18.3% from the prior quarter. Over 3 fiscal years it compounded at +2.4% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 15 analysts of $50.19M (-48.3%) for the fiscal year ending Dec 2026, a slowdown from the -7.9% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$36.28M+18.3% QoQ
Last fiscal yearDec 2025
$97.1M-7.9% YoY
LTMJun 2026
$139.03M+19.2% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.4%-65.9%-78.4 pp
1 year-7.9%-48.3%-40.4 pp
3-year CAGR+2.4%+45.9%+43.5 pp
5-year CAGR+45.3%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
97.1M USD
Year-over-year change
-7.9%
4-year CAGR
+5.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How DNLI compares with its peers on the latest reported figures

  • DNLI's LTM Jun 2026 selling, general & admin of $139.03M is the 3rd highest of the 11 companies compared; the peer median is $65.18M.
  • Its year-over-year change of +19.2% is the 5th highest of 11, against a peer median of +13.6%.
  • Selling, general & admin amounts to 3857.6% of revenue for DNLI, versus a peer median of 116.2%.
DNLI Competitors Peer median
Selling, General & Admin for DNLI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
NBIXNeurocrine Biosciences, Inc.LTM Sep 2026$1.43B +24.9%+15.4%38.5%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$584.98M +66.3%+37.9%61.0%
DNLIDenali Therapeutics Inc.LTM Jun 2026$139.03M +19.2%+2.4%3857.6%
PRAXPraxis Precision Medicines, Inc.LTM Sep 2026$117.61M +115.1%-0.3%—
BHVNBiohaven Ltd.LTM Jun 2026$99.69M -4.4%-6.7%—
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$74.79M +15.8%-20.9%—
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$55.57M -17.1%+24.5%—
ALECAlector, Inc.LTM Mar 2026$47.37M -20.9%-4.0%257.2%
RAPPRapport Therapeutics, Inc. Common StockLTM Mar 2026$34.27M +37.9%+181.0%171.4%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$10.32M -12.0%-7.1%—
PMNProMIS Neurosciences, Inc.LTM Jun 2026$7.78M +11.4%-90.2%—
Peer median (excluding DNLI) $65.18M+13.6%-2.1%116.2%

Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue48.66M108.46M330.53M00
Cost of Revenue000011.18M
Gross Profit48.66M108.46M330.53M0(11.18M)
Gross Margin100.0%100.0%100.0%——
Research & Development265.35M358.73M423.88M396.44M418.78M
Selling, General & Admin79.06M90.48M103.35M105.44M97.1M
Operating Expenses344.41M449.21M527.23M487.34M544.16M
Depreciation & Amortization8.59M10.38M16.73M8.99M14.81M
EBITDA(282.56M)(315.59M)(128.47M)(492.89M)(497.63M)
EBITDA Margin-580.7%-291.0%-38.9%——
Operating Income(295.75M)(340.74M)(196.7M)(487.34M)(555.34M)
Operating Margin-607.8%-314.2%-59.5%——
Interest Income4.6M14.77M51.51M64.64M42.9M
Interest Expense00000
Other Income / Expenses4.6M14.77M51.51M64.64M42.9M
Income Before Tax(291.16M)(325.97M)(145.19M)(422.71M)(512.44M)
Pre-Tax Margin-598.3%-300.5%-43.9%——
Income Tax Expense(575K)21K30K68K102K
Net Income(290.58M)(325.99M)(145.22M)(422.77M)(512.54M)
Net Margin-597.2%-300.6%-43.9%——
EPS (Basic)(2.39)(2.60)(1.06)(2.57)(2.97)
EPS (Diluted)(2.39)(2.60)(1.06)(2.57)(2.97)
Weighted Avg Shares121.52M125.53M137.37M164.47M175.46M
Weighted Avg Shares (Diluted)121.52M125.53M137.37M164.47M175.46M

Denali Therapeutics Inc.

NASDAQ:DNLI

Intrinsic Alpha fair value

Locked

Current Price

$18.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.